Skip to main content
Premium Trial:

Request an Annual Quote

SCRI to Use DxTerity Reagents in Cardiac Test

NEW YORK (GenomeWeb News) – DxTerity Diagnostics today said that the Scottsdale Clinical Research Institute in Arizona will use the firm’s Quenched Auto Ligating reagents for development of a microRNA-based cardiac test.
 
The test will measure the expression of a microRNA biomarker in heart biopsy tissue samples, which has been shown to correlate with post-operative heart arrhythmia. DxTerity said that SCRI will use its QUAL reagents to validate the biomarker’s ability to reveal at-risk patients before an arrhythmia strikes.
 
“SCRI and DxTerity have established an alliance to develop bioassay platforms supporting the vision of personalized medicine,” said Mark Slater, VP of research at SCRI. “Our shared goal is to accelerate the development and use of novel predictive biomarkers by physicians, and to improve patient outcomes.”
 
Rancho Dominguez, Calif.-based DxTerity noted that the project is being partially funded by the Ibis Foundation of Arizona.

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.